Annovis Bio Partners with NeuroRPM to Enhance Parkinson's Trial with AI

Annovis Bio, Inc. (ANVS) has announced a strategic partnership with NeuroRPM to integrate an FDA-cleared AI platform into its ongoing Phase 3 clinical trial for Parkinson's disease. This collaboration involves the use of advanced wearable technology designed to continuously monitor core symptoms of the disease in real-world environments. By moving beyond periodic clinical observations, the study aims to capture a more comprehensive dataset regarding disease progression and patient response to treatment. The integration of NeuroRPM's technology is expected to enhance the integrity of the clinical data collected during this critical phase of development. This move underscores a growing trend in the biotech industry to leverage digital health tools for more precise regulatory outcomes. Investors view this development as a positive step toward strengthening the clinical profile of Annovis Bio's therapeutic pipeline.

Sources:MyChesCointellectia.aimarketscreener.compharmanow.liveannovisbio.cominvesting.comstockanalysis.comstreetinsider.comstocktitan.netmarketbeat.comtrial.medpath.comlongevity.technology